Wistar Institute scientists report that combining the kidney cancer drug axitinib with a 4-1BB agonist overcame myeloid cell ...
Phase 3 HER2CLIMB-05 trial demonstrates a 35.9% reduction in risk of disease progression or death with maintenance tucatinib combination.
Chemists at the Max-Planck-Institut für Kohlenforschung have developed a two-step, nickel-catalysed method that builds ...
Mizuho names Oracle its top October stock pick with a $320 target, adding six more companies including UnitedHealth Group and Wyndham Hotels.
The company has unveiled positive results from a Phase III study. The trial evaluated the efficacy of Zenbexus combined with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results